Zoryve™ (roflumilast) – New drug approval
July 29, 2022 - Arcutis Biotherapeutics announced the FDA approval of Zoryve (roflumilast), for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.
Download PDF
